Alvotech posts H1 net loss as manufacturing, quality upgrades curb product revenue, company says
ALVO•H1 results turn to loss as revenue falls
For the six months ended June 30, 2026, Alvotech reported a net loss of USD 65.79 million, compared with a profit of USD 141.72 million a year earlier.
Revenue fell as manufacturing and quality system enhancements following the 2025 Reykjavik FDA inspection constrained product availability.
Product revenue declines while milestones support license income
Product and service revenue dropped 48% to USD 105.94 million, mainly from AVT02 and AVT04 sales through commercialization partners.
License and other revenue rose to USD 105.7 million on development and regulatory milestones across the pipeline.
Higher finance costs and sharply lower fair-value gains in finance income weighed on results. Cash and equivalents ended at USD 142.8 million.
